Pregabalin
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Rotator Cuff Tears
Conditions
Rotator Cuff Tears, Central Sensitisation, Neuropathic Pain
Trial Timeline
Sep 1, 2024 → May 1, 2026
NCT ID
NCT06367998About Pregabalin
Pregabalin is a approved stage product being developed by Viatris for Rotator Cuff Tears. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06367998. Target conditions include Rotator Cuff Tears, Central Sensitisation, Neuropathic Pain.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06367998 | Approved | Recruiting |
Competing Products
5 competing products in Rotator Cuff Tears
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| BMP-655/ACS+Standard of care or Standard of care + BMP-655/ACS+Standard of care or Standard of care + BMP-655/ACS+Standard of care or Standard of care | Pfizer | Phase 1 | 32 |
| BMP-655/ACS or Standard of Care + BMP-655/ACS or Standard of Care + BMP-655/ACS or Standard of Care | Pfizer | Phase 1 | 32 |
| Single Injection of Local Anesthetic | Baxter | Phase 1 | 30 |
Other Products from Viatris
Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82
FlecainideApproved
82